Thousands of adults with multiple sclerosis in England can now access fampridine on the NHS, making it the first medicine designed to improve walking speed and ability. Announced by NHS England, the twice-daily therapy aims to boost nerve signals, offering renewed independence for patients facing mobility challenges.
A New Twice-Daily Signal Booster for MS Mobility
Adults living with multiple sclerosis in England can now access a targeted treatment designed to address one of the condition’s most limiting symptoms. Fampridine is available routinely on the NHS, marking the first time a medicine specifically built to improve walking ability has been offered through the health service as reported by NHS England. Taken as a pill twice daily, the medication acts as a signal booster for nerves damaged by MS, allowing electrical messages to travel more effectively to muscles.
Clinical trials found that the medication improved walking speed in 43 per cent of patients while also helping individuals stay on their feet for longer periods according to AOL. For patients managing a lifelong neurological condition marked by weakness, fatigue, and coordination problems, these improvements can alter daily routines.
Eligibility Rules and Trial Periods for Patients
The rollout targets a specific subset of the more than 120,000 people living with MS in England noted the BBC. NHS England estimates that approximately 5,000 patients will be eligible for the treatment in its first year. Prescription criteria rely on the Expanded Disability Status Scale. The drug is designated for adults with any type of MS whose walking score falls between four—meaning they can walk about 500 metres without an aid or rest—and seven, where individuals are largely restricted to a wheelchair and unable to walk further than five metres.
Patients do not receive an open-ended prescription immediately. Instead, they try the medication for a trial period lasting between two to four weeks. Walking ability is assessed before and after this window, and only those who demonstrate a clear benefit are permitted to continue taking the drug under regular clinical reviews.
Relief for Patients Facing High Private Costs
Prior to this NHS availability, patients wishing to use the treatment faced steep out-of-pocket expenses if they could access it at all. Aysen Slack, a 65-year-old MS patient from Eastbourne, previously chose to pay for the pills privately after learning about them, but found the financial burden unsustainable over time.
“Fampridine seemed to be working well for me, but [it] … was a significant expense and I could not keep doing that forever. So I had to make the difficult decision to stop taking it.”
Aysen Slack, MS patient from Eastbourne
Slack noted that her mobility has declined significantly, requiring the use of sticks even inside her flat. She welcomed the decision to bring the drug to the health service so she could attempt treatment again highlighted by BBC News.
Institutional Assessment and UK-Wide Alignment
The NHS rollout follows an evaluation by the Clinical Priorities Advisory Group, which reviews specialist medicines and devices for patient benefit and value for money stated NHS England. This pathway handles treatments not evaluated by the National Institute for Health and Care Excellence, such as those outside standard licensed indications. The decision also brings England into alignment with other UK nations, as fampridine has been available on the NHS in Wales since 2019 and in Scotland since 2020 reported AOL.
“Walking difficulties can have a huge impact on the freedom and independence of people with MS, so this signal-boosting pill could be life-changing for thousands of patients. For some, even a modest improvement could mean getting around the house more easily, going out with greater confidence and living more independently.”
Prof Frankie Swords, NHS national medical director
What Next for MS Services and Independent Living
Ceri Smith, head of policy and evidence at the MS Society, described the medication as the only licensed treatment that helps improve walking ability and speed for some individuals with the condition, noting it can help people stay in employment or live more independently.
Specialists emphasize that local clinics must now receive adequate support. Professor James Palmer, national medical director for specialised services at NHS England, pointed out that patients who spent years relying solely on physiotherapy or walking aids now have access to a distinct medical option noted in official NHS announcements.
Related reading
